1. Introduction
===============

Malaria, a profound human health problem that has gained importance and continues to stimulate research, affecting the major tropical and subtropical regions of the world, including parts of America, Asia, and Africa. Each year approximately 515 million cases of malaria are reported. According to a recent report, 214 million malaria cases were reported worlwide in 2015. That year saw an estimated 438,000 malaria deaths worldwide, and 90% of those deaths occurred in Africa followed by 7% in Southeast Asia and 2% in the Eastern Mediterranean region (2%) \[[@B001]\]. Strategies such as vaccination, anti-malarial drug formulation, and vector control have been undertaken to combat this parasitic disease. Among these, parasitical drugs are the main line of defense. Unfortunately, the emergence of malarial parasites with resistance to existing drugs is a burning crisis \[[@B002]\]. Therefore, the design of a new line of anti-malarial drugs would represent a major breakthrough that needs to be explored.

The recent identification of a chloroplast-like organelle called the apicoplast in malarial parasites has great implications for overcoming their resistance to anti-malarial drugs. The apicomplexan plastid, which is called a apicoplast, arises from the endosymbiotic process, just as with other plastids, and is integrated into the parasite's function \[[@B003]\]. The nuclear gene of the parasite is post-translationally targeted to the organelle via the secretory pathway via the endoplasmic reticulum. Vesicles bearing toxoplasma apicoplast membrane proteins persist following loss of the relict plastid or golgi body disruption \[[@B004]\]. On the other hand, the apicoplast appears to serve its host with multiple functions, though it apparently lacks the capacity to photosynthesize; however, it retains the typical plastid functions, such as fatty acid, isoprenoid, and heme syntheses, among others. It also bears all cellular processes such as deoxyribonucleic acid (DNA) replication, transcription, translation, and post-translational modification. The products of the metabolic pathways might be exported from the apicoplast for the use of the parasite itself, and some components of the products are essential for host cell invasion \[[@B005], [@B006]\]. Each of these processes is a potential drug target because they differ from the processes in the host, which are fundamentally eukaryotic. In this review, we will examine the apicoplast's genome organization and structural peculiarities, as well as anti-malarial drugs designed to target the apicoplast.

2. Present status of anti-malarial drugs
========================================

Malaria is caused by the protozoan parasite *Plasmodium*. Only four types of the *Plasmodium* parasite can infect humans. People get malaria because of their having been bitten by an infective female *Anopheles mosquito* that carries the apicomplexan parasite, *Plasmodium*. The prophylactic drug treatments against malaria are often too expensive for most people who live in endemic areas. Most adults from endemic areas possess partial immunity in terms of resistance to those drugs and become susceptible to severe malaria \[[@B002]\].

The emergence of resistance to existing drugs among malarial parasites has been a deepening crisis. Resistance to the most effective classes of anti-malarial drugs has emerged, and this has been responsible for the recent increase in malaria-related mortality, particularly in Africa. The genetic events that confer anti-malarial drug resistance (while retaining parasite viability) are thought to be autonomous and independent of the drug used. The causes of drug resistance are generally mutations or changes in the copy number of genes relating to the drug's parasite target. However, influx/efflux pumps, which alter the intraparasitic concentrations of the drug, also help to develop the resistance. For example, chloroquine resistance in *Palsomdium falciparum* (*P. falciparum*) may be multigenic and is initially conferred by mutations in a gene encoding transporter *Palsomdium falciparum* chloroquine-resistance transporter (PfCRT). Resistance to atovaquone results from point mutations in the gene cytochrome b (cytB), coding for cytB \[[@B007]\]. Resistance to mefloquine (MQ) and other structurally-related arylaminoalcohols in *P. falciparum* results from duplications in *Palsomdium falciparum* multi-drug resistance gene (Pfmdr), which encodes the p-glycoprotein pump (Pgh) \[[@B008]\]. For *P. falciparum* and *Plasmodium vivax* (*P. vivax*), resistance to pyrimethamine and cycloguanil results from the sequential acquisition of mutations in dihydrofolate reductase (DHFR) \[[@B009], [@B010]\]. The resistance to such anti-malarial compounds in malarial parasites is thought to appear relatively frequently, and recent reports have suggested the emergence of resistance toone of the most widely used anti-malarial drugs, artemisinin \[[@B011]\].

Current reports have suggested that patients with severe malaria who were treated with quinine did not recover \[[@B012]\]. Resistance to chloroquinine is associated with a resistance transporter PfCRT, and the mutated form of the PfCRT gene. Moreover, additional mutations on the Pfmdr1 are also linked with the resistance \[[@B013]\]. On the other hand, recent evidence has shown resistance to MQ to be due to a mutation in Pfmdr-1 \[[@B014]\]. Piperaquine (PPQ) resistance was recently reported and was thoughtto be due to a variation on chromosome 5 that includes Pfmdr-1 \[[@B015]\]. Point mutations in the *Palsomdium falciparum* dihydrofolate reductase (PfDHFR) and the *Palsomdium falciparum* dihydropteroate synthetase (PfDHPS) genes confer resistance to sulfadoxine-pyrimethamine (SP) \[[@B016]\]. Point mutations and copy number variations in Pfmdr-1 have also been implicated in resistance to artemisinin. However, the exact mechanism is unclear, and clinical trials were unable to identify the role of Pfmdr-1 in artemisinin resistance \[[@B017], [@B018], [@B019]\]. These findings suggest that prevention of drug resistance will be very problematic; thus, control efforts would be better directed at limiting the subsequent spread of resistance (Table [1](#T001){ref-type="table"}). For this reason, new lines of drugs must be explored before existing drugs lose their efficacy.

3. Emergence of the apicoplast
==============================

The recent identification of the apicoplast in malarial parasites has insightful implications for drug therapies to overcome the problem of resistance. To assess the potential of the apicoplast as a drug target, we need to understand how this vital organelle arises. Consensus phylogenetic analyses have divided eukaryotes into six supergroups. Apicomplexa in the stramenophile, alveolate and rhizaria supergroups is distinct from its animal hosts. Apicomplexa started their evolutionary journey to being a parasite from aphotosynthetic entity; a path that has recently been established by the discovery of fully photosynthetic apicomplexan-like algae. Phylogenetic studies reveal that these two groups and the dinoflagellate algae arose from a common photosynthetic ancestor. Evolutionary data suggest that Apicomplexa are often confused with 'animal cells with a plastid' or 'parasitic plants'. However, that is not so. Rather, they have many unique biological characteristics with a unique evolutionary history \[[@B010]\]. The apicoplast retains the basic features of a plastid, which makes this organelle a promising drug target \[[@B020], [@B021], [@B022]\]. However, that the apicoplasts differ markedly from plant plastids is increasing apparent. This divergence of the apicoplast was shown in a recent phylogenetic analysis of plastid origins, in which the apicoplast was placed in a completely evolutionarily distinct group from that of the plastids of green plants and Archaeplastida algae. Evolutionary divergence and the large number of unknown genes within this novel apicomplexan-related plastid lineagepresent considerable opportunities in targeting the apicoplast with anti-malarials.

4. General structure and genome organization of an apicoplast
=============================================================

All apicomplexan parasites, except *Cryptosporidium sp*., possess three active components for replication/transcription/ translation: the nucleus, the apicoplast, and the mitochondrion. As *Cryptosporidium sp*. bears mitochondria that do not contain DNA, noorganelle of an endosymbiotic origin containing DNA, such as an apicoplast, could have evolved in the genomic machinery of that organism \[[@B023]\]. On the other hand, although an organism like *Chromera velia* (*C. velia*) contains a photosynthetic plastid, the majority of apicomplexan parasites contain either a non-photosynthetic plastid or no plastid at all. This indicates that the apicomplexan malarial parasites might have evolved from a significant and essential organelle like an apicoplast \[[@B024]\]. As *C. velia* contains the original apicoplast, it has been used as a model target for anti-malarial drug development.

The nucleus contains a 23-Mb nuclear genome composed of 14 linear chromosomes with approximately 5,300 genes whereas specialized organelles each contain a circular genome: a 35-kb apicoplast genome with around 50 genes and a 3-kb mitochondrial genome encoding only 3 protein genes and ribosomal RNA (rRNA) genes. The apicoplast is a non-photosynthetic plastid-like organelle of protozoan parasites of Apicomplexan-including pathogens like *Plasmodium*, *Toxoplasma* and *Cryptosporidum*. This organelle might have originated as a process of secondary endosymbiosis. However, a hypothesis is that apicomplexans were once able to use apicoplasts to synthesize energy by photosynthesis. Therfore, the ancient apicomplexans and their related progenitors might have had a symbiotic relationship with their surrounding coral reef. To achieve that, those early organisms would have possessed a working chloroplast. However, over the course of time, that autotrophic ability was lost, and apicomplexans slowly evolved to become parasitic species dependent on their hosts for survival.

The apicoplast is ovoid and intimately associated with mitochondria. It shows three distinct membrane-like structures: an inner envelope membrane (IEM), an outer envelope membrane (OEM) and an outer membrane system (OMS). In *Plasmodium sp*. and *Toxoplasma sp*., the apicoplast seems to be surrounded by a basic set of membranes. Most of the genes appearing in an apicoplast are involved in organelle transcription and translation \[[@B006], [@B010], [@B020]\].

5. Apicoplast as a drug target
==============================

Creating food from carbon dioxide and sunlight is not the only task that apicoplasts perform for their host; they are also major sites of a number of anabolic processes whose products are supplied to the surrounding host cell. These metabolic services make plastids indispensable to plant and alga, even to non-photosynthetic ones like apicomplexan parasites. The *Plasmodium* apicoplast was revealed to be a stripped-down version of a chloroplast, in which about 500 nucleus-encoded and apicoplast-targeted proteins lie and are combined with 35 proteins encoded within the apicoplast by its circular genome.

The first portrait of apicoplast metabolic pathways showed the apicoplast as carrying four identifiable metabolic pathways, isoprenoid precursor synthesis, fatty acid synthesis, heme synthesis and ironsulfur cluster biogenesis, and as having the functions of genome replication, transcription, translation, post-translational modification and protein turnover \[[@B006], [@B020]\]. Among all of these apicoplast functions, fatty acid synthesis, isoprenoid precursor synthesis and "housekeeping" functions are clearly bacterial in nature and are, therefore, potential targets for existing anti-biotic drugs because they differ from the processes in the host, which are fundamentally eukaryotic. Many such anti-biotics have been successfully tested on *Plasmodium* in culture \[[@B019], [@B020]\].

As a drug target, the apicoplast can be considered to be an important organelle in which all cellular processes, such as DNA replication, transcription, translation, post-translational modification, catabolism and anabolism, occur. Each of these processes is bacterial in nature and potentially a drug target.

5.1. Drugs targeting apicoplast DNA replication
-----------------------------------------------

Replication of apicoplast DNA occurs in a rolling circular mechanism initiated at sites outside the inverted repeat. However, the inverted repeat is not coded by the apicoplast genome itself. That nuclear gyrase B (GyrB) encodes a functional subunit of the *P. falciparum* gyrase involved in apicoplast DNA replication has been clear for some time.

Fluro quinolene ciprofloxacine is a selective and target- specific inhibitor of prokaryote-type DNA gyrase, which stabilizes DNA complexes that are nicked. The coding sequences for two recognized apicoplast-targeted proteins, gyrase A (GyrA) and GyrB, have been identified from genomic information on *P. falciparum* \[[@B025]\] and suggest that the apicoplast utilizes these molecules for its DNA replication. The GyrA subunit contains DNA cleavage and wrapping domains whereas the GyrB subunit contains adenosine triphosphase (ATPase) and DNA binding/GyrA interaction domains, exhibiting strong homology to their *Escherichia coli* (*E. coli*) counterparts.

The aminocoumarin drug novobiocin, which inhibits the ATPase activity of GyrB in *E. coli*, was shown to specifically and competitively inhibit the apicoplast's ATPase activity and the DNA replication in *P. falciparum*, leading to a lag in trophozoite-to-schizont conversion \[[@B026]\]. Ciprofloxacin has been shown to inhibit apicoplast DNA replication in *P. falciparum*, sparing the nuclear replication of the parasite \[[@B027]\]. Novobiocin also inhibits PfGyrB by disrupting the activity of its ATPase, which causes parasite death in cultures. On the other hand, it also reduces the apicoplast/nuclear DNA ratio, which indicates that the drug targets apicoplast DNA replication \[[@B028]\]. Several derivatives of quinolones and fluoro quinolones have also been shown to have anti- parasiticidal activity against *Toxoplasma gondii*, further supporting apicoplast DNA replication as the drug target of choice in the parasite \[[@B029]\].

Recent studies have revealed that apicoplasts are abnormal in the progeny of doxycycline-treated parasites, as evidenced by a block in apicoplast genome replication and a failure to elongate and segregate during schizogeny. Clindamycin and functionally-related compounds also inhibit plastid replication upon drug application, as revealed by the work reported in Refs. \[[@B030], [@B031]\].

5.2. Drugs targeting apicoplast transcription
---------------------------------------------

Transcription in plastids utilizes an RNA polymerase homologous to that of cyanobacteria and other eubacteria. Like a bacterial genome, the polymerase of an apicoplast recognises − 10, − 35 promoters and transcribes polycistronic RNAs from operons. The apicoplast genome also encodes the *β* and the *β*\' subunits of the polymerase \[RNA polymerase gene (Rpo) RpoB, RpoC1, and RpoC2 genes\], which strongly suggests that it uses a transcription system similar to that of bacteria \[[@B032]\].

The eubacterial form of transcription is extremely sensitive to the anti-biotic rifampin, showing anti-malarial activity both *in vitro* and *in vivo*. Furthermore, rifampin has been shown to be selective in targeting transcripts of apicoplast- encoded genes. The *α*2, *β* polymerase of an apicoplast is highly sensitive to rifampin, and the anti-malarial activity of rifampin suggests that this drug blocks apicoplast transcription.

A phage-like RNA polymerase was recently identified in *P. falciparum* \[[@B033]\]. However, it is believed to be the mitochondrial polymerase. No drugs that are specific to phagetype polymerase are known to us. The apicoplast genome encodes the RpoB, RpoC1 and RpoC2 subunits of an RNA polymerase. Indirect transciption inhibition by blocking translation of these RNA polymerase subunits seemed promising to several researchers. In that approach, the natural cyclic oligopeptide anti-biotic thiostrepton was found to reduce the expressions of RpoB and RpoC \[[@B034]\]. Similarly, anti-biotic doxycycline also appeared to reduce the expressions of those two subunits and to inhibit the synthesis of nucleotides and deoxynucleotides \[[@B035]\].

The anti-biotic rifampin (or rifadin) also reduces the expression of RpoB and RpoC transcripts without the delayed- death effect \[[@B036]\]. However, rifampin does not target translation of RNA polymerase subunits, but rather transcription by binding to RNA polymerase. Then, why does targeting different elements of transcription/translation result in different death phenotypes? The answer may lie in the off-apicoplast targets of some of the drugs like thiostrepton. However, another explanation might lie in the extra-apicoplast utilization of apicoplast-borne RNA.

5.3. Drugs targeting apicoplast translation machinery
-----------------------------------------------------

At present, no direct evidence for translation in the apicoplast exists. However, ribosome-like particles, which have sizes similar to those of bacteria and polysomes containing plastid rRNA and messenger RNA (mRNA), can be obtained from the erythrocyte stages of parasites. This intervention provides indirect evidence that apicoplast genes are certainly translated \[[@B037]\]. Recently, a single putative organellar *Palsomdium falciparfum* initiation factor (PfIF)-1 was found to be targeted at the apicoplast. This typical translation initiation factor interacts with ribosome and exhibits nucleic-acid binding activity, which mediates transcription anti-termination. This suggests a prominent functional role for PfIF-1 in the apicoplast genome, indicating that PfIF-1 may be a good target for a drug \[[@B038]\].

Numerous drugs have been developed to target the protein synthesis pathways of apicoplasts. In *P. falciparum*, most anti-biotics instigate delayed death by inhibiting translation and specifically interacting with the apicoplast's ribosome. Their mode of action is associated with the prevention of nascent peptide elongation, mostly interfering with the peptide exit tunnel formed within ribosomal subunits \[[@B039], [@B040], [@B041]\].

A complete review of nuclear, apicoplastic, and mitochondrial translation, which summarizes the current efforts in understanding protein translation in *Plasmodium*, has recently been published \[[@B042]\]. Lincosamides and macrolides inhibit protein synthesis by binding to the peptidyl transferase domain of the prokaryote-type 23s synthesis after binding to the peptidyl transferase domain of the prokaryote-type 23s RNA. Two thiopetides, such as thiostrepton, micrococcinetc., also bind to 23s rRNAs, specially with the GTPase domain, where they interact with key nucleotides. Thus, *P. falciparum* has shown high sensitivity to thiostrepton and micrococcin.

Studies examining the effect of drugs that target apicoplast 'housekeeping' processes, like replication, transcription and translation, have revealed an unfamiliar aspect of apicomplexan biology, which is called 'delayed death' \[[@B030], [@B042]\], where daughter cells find a new infection but fail to grow and produce further progeny. When growing in human cells, *Plasmodium sp*. undergoes a complex division process to produce multiple daughter cells within a single parasitophorous vacuole. These daughter cells are released by falling out of the vacuole and invading new cells. When treated with compounds inhibiting apicoplast genome replication and transcription, protein translation, post-translation modification or protein turnover, the parasites continue to grow, divide and release daughter cells that are still capable of invading new host cells \[[@B043], [@B044]\]. The effect is identical to the growth pattern of apicoplast segregation mutants lacking an apicoplast. This suggests that 'delayed death' relates to the function of the apicoplast and not simply to accessibility of the drug to the parasites. In *P. falciparum*, thecase of delayed death is less clear. Chloramphenicol does not have a delayed effect in *Plasmodium* as compared with *Toxoplasma gondii*. However, thiostreptom is reported to be a slow-acting drug.

5.4. Drugs that target fatty acid biosynthesis
----------------------------------------------

The presence of a distinct and prokaryotic-like pathway for the biosynthesis of fatty acids in parasites offers tremendous potential for parasite-selective drugs. Bacteria and chloroplasts synthesize fatty acids by using a type-II fatty acid synthase (FAS)-II. This utilizes several dissimilar enzymes (proteins) for the steps in the FAS biosynthetic pathway. Emerging evidence indicates that the apicoplast harbors a type-II FAS machinery. This anabolic pathway may be involved in the synthesis of the lipids required by the apicoplast. A suggestion is that *P. falciparum* synthesizes fatty acids to form a parasitophorous vacuole (PV) during invasion of host erythrocytes, and the requirement for apicoplast activity for successful infection is consistent with this postulate.

The first breakthrough in the identification of a fatty acid biosynthesis pathway was the identification of genes encoding apicoplasts that were homologues of several bacterial type-II fatty acid biosynthesis sub-units. One of these sub-units, *β*-ketoacyl-acyl carrier protein (ACP) synthase (FabH), is targeted by the anti-biotic thiolactomycin, showing *in vitro* inhibition of *Plasmodium*. Another type- II FAS sub-unit, enoyl-ACP reductase (FabI), has also been identified in the *P. falciparum* apicoplast \[[@B045]\]. Thiolactomycin is drug that inhibits type-II fatty acid synthetase, and several analogs of this have shown almost five-fold greater efficacy.

Cerulenin targets *β*-ketoacyl-ACP sythetase I and II and inhibits *Plasmodium* \[[@B046]\]. Furthermore, triclosan is another drug that is selective by targeting FabI and that has shown efficacy as an anti-malarial in a mouse model. Recently, triclosan was shown to inhibit purified *P. falciparum* enoyl-ACP reductase, as well as parasite growth, *in vitro* and *in vivo*. However, similarities between the FabI proteins of *E. coli* and *P. falciparum* suggest that a similar mutation might result in triclosan resistance in *P. falciparum*, thereby compromising the usefulness of triclosan as an anti-malarial \[[@B047]\]. Recent studies have shown that FASII is not a suitable target for drug design because the drugs targeting FASII were found to be effective only in *in vitro*, not in *in vitro*, due to different patterns of essentiality \[[@B042], [@B045], [@B048], [@B049]\].

5.5. Drugs that target isopenetyl diphosphate (IPP) synthesis
-------------------------------------------------------------

Isopentenyl diphosphate (IPP) is the precursor for a structurally-diverse isoprenoid class of compounds. In animals and plants, IPP is synthesized via the classical mevalonate pathway. An alternate pathway proceeding via 1-deoxy-D-xylulose 5-phosphate (DOXP) has recently been elucidated in chloroplasts and bacteria, and two enzymes from this pathway have been identified in *P. falciparum* \[[@B050]\]. One of those enzymes, DOXP reductoisomerase, is the target of the anti-biotic fosmidomycin in recombinant *P. falciparum*. DOXP reductoisomerase is inhibited by fosmidomycin. It also inhibits the growth of *P. falciparum* in and is known to cure malaria in a mouse model \[[@B051], [@B052]\]. Assays to test potential inhibitors of DOXP enzymes in bacterial systems and in plant test systems have already exposed new inhibitors of DOXP synthase (the first step of IPP synthesis). Remaining to be seen is whether or not these compounds act against *P. falciparum* DOXP synthase, and if they do, whether they inhibit parasite growth.

On the other hand, during the blood stages, parasites lacking an apicoplast can grow in the presence of IPP, indicating that it is the only metabolite produced in the apicoplast that is needed outside the organelle. One of the isoprenoid biosynthesis enzymes is predicted to dependon iron-sulfur (FeS) cluster cofactors \[[@B053], [@B054]\]. Recently, reaserchers have targeted this cofactor as a potential drug target. Anti-malarial drugs like primaquine have been used to kill the gametocyte forms of *P. falciparum* and the hepatic forms of *P. vivax*. However, the mechanism of action for this drug is poorly understood. Though its mechanism of action is still poorly understood, recent studies have indicated that the drug might targets Fe-S cluster proteins and, thus, show anti-malarial efficacy \[[@B055], [@B056]\].

5.6. Drugs that target heme synthesis
-------------------------------------

Animals are known to synthesize heme from glycine and succinyl CoA via the Shemin pathway. However, plastids use an unusual pathway starting with glutamate ligated to transfer RNA (tRNA)-Glu. The Shemin pathway apparently occurs in *P. falciparum*, presumably in the mitochondrion and cytosol, but a cyanobacterial-type heme pathway may also exist in the apicoplast. For instance, a likely apicoplast targeted dehydratase (a key enzyme of heme synthesis) has been identified in *P. falciparum*, and it has groups with predominantly Mg^2+^ binding plastid dehydratases rather than the Zn^2+^ binding mitochondrial equivalent \[[@B057], [@B058]\]. However, another heme synthesis enzyme that bears an apparent mitochondrial-targeting signal has also been identified. Moreover, a recent study has also speculated that *P. falciparum* uses an additional dehydratase imported from the erythrocyte cytosol.

Localization of the enzymes recognized to date and characterization of the remaining unidentified enzymes of the heme synthesis pathway should help clarify this currently confusing issue. Heme synthesis is an established target for herbicides both in the blood and the liver stages of the parasites, and given that *P. falciparum* possesses at least one plant-like heme synthesis enzyme, the elucidation of the full pathway should further illuminate potential drug targets \[[@B059], [@B060], [@B061], [@B062]\].

5.7. Recent advances and application of bioinformatics on apicoplast targeted drug designing
--------------------------------------------------------------------------------------------

The structures of the inhibitors were extracted from the Protein Data Bank (PDB) files of a large subunit of the 70S ribosome of an apicoplast co-complexed with respective inhibitors such as chloramphenicol, clindamycin, erythromycin, azithromycin and thiostrepton. Molecular docking was performed, by using Autodock ver. 4, on ribosome models with ribosome as a receptor to dock the inhibitors of interest \[[@B063]\]. Kollman charges were assigned with 40 × 40 × 40 grid points of 0.375 Å spacing. One hundred Autodock runs were performed for each inhibitor. To validate the docking program, we used Autodock ver. 4 to dock the inhibitor co-complexed with a template in which the limit of Autodock to read the maximum number of atoms in the macromolecules was kept constant at the default value; therefore, 35 Å around the ligands was considered only after superimposing the modelled structure on the *E. coli* ribosome structure \[[@B064]\].

On the other hand, apicoplast-targeted tRNA guanine transglycosylase and its potential inhibitors were also designed by using docking and simulation studies \[[@B065]\]. In this field, computational models have also been generated, and on the basis of which apicoplast-targeted proteins were identified, target-specific drugs were designed \[[@B066]\].

6. Future aspects
=================

Anti-malarial drug design targeting apicoplasts, like organelles, has enetered a new dimension in the development of parasitical drugs. Genetic evidence confirmed that apicoplast FAS is not essential *in vivo*. Thus, a clearer understanding of how human malaria parasites respond to loss of FAS in the liver stage is needed before this pathway can be enlisted as a viable drug target. The heme biosynthesis pathway is biologically fascinating as it shows a curious nature in apicomplexan parasites. During their evolution, apicomplexans have combined the Shemin pathway. This pathway involves all the enzymatic reactions in the mitochondrion and cytosol with the plastid localized pathway found in plants to finally form a chimeric pathway where synthesis begins in the mitochondrion, proceeds through the cytosol and apicoplasts, and is eventually completed in the mitochondrion. Whether apicoplast-deficient parasites remain viable in their sexual or liver stages has not yet been determioned. Therefore, interpreing the role of heme synthesis in these life stages is difficult, but again, heme synthesis may play a vital a role in gametes and liver-stage parasites. Considering this, one can appreciably state that heme synthesis may be an important drug target for transmission blocking and prophylaxis.

The malaria parasite can be killed both by inhibitors like fosmidomycin, which is known to have a direct action on isoprenoid precursor biosynthesis, and by many other common anti-biotics, which act indirectly by disrupting the viability of the apicoplast itself. Beside this, dual targeting drugs have been designed and applied. A dual targeted aminoacyl-tRNA synthase in *P. falciparum* changes both the cytosolic and the apicoplast tRNACys and inhibits the growth of the parasite \[[@B067], [@B068]\]. At present, research on apicoplasts has established a detailed prediction of an apicoplast metabolism in *Plasmodium sp* based on a bioinformatics approach \[[@B063]-[@B066]\]. Furthermore, metabolic maps, the functional significance of the apicoplast, and the importance of the organelle to the parasite have been analyzed extensively. Researchers have identified the malaria plastid as having a broad range of potential new chemotherapeutic target options in combating malaria. Already, a large number of anti-malarial compounds with assumed targets in the apicoplast have been identified. If these target options are successful in trials, that would be a huge advancement in the field of drug development. Progress has been rapid due to the availability of genome data for the apicoplast \[[@B021], [@B022], [@B042], [@B069]\].

In conclusion, the mode of action and the potential mechanisms of resistance to anti-malarial drugs, such as chloroquine, atovaquone, mefloquine, pyrimethamine, cycloguanil, artemisinin etc. \[[@B007], [@B008], [@B009], [@B011]\], have been deciphered. However, the development of new anti-malarial drugs targeting apicoplasts may represent a significant breakthrough in drug development, provided future clinical trials are successful (Fig. [1](#F001){ref-type="fig"}). Now, we are in a sphere of activities where a new system of drug development using apicoplasts as a targets in *Plasmodium* can be seen on the horizon. This review has discussed the immense opportunities that are at hand to neutralize the curse of malaria on human lives, but further trials are needed if the unstinted benefits of these new drugs are to be harvested.

![Schematic representation of apicoplast-targeted anti-malarial drugs and their modes of action.](2093-6966-v19-n01-007-g001){#F001}

###### Anti-malarial drugs and their mechanisms of resistance

  Name of anti-malarial drug   Mechanism of resistance
  ---------------------------- -------------------------------------------------------------------------------------------------------------------------------
  Chloroquinine                Mutations in a gene encoding a transporter, PfCRT and mutations on the Pfmdr-1 \[13, 17\]
  Atovaquone                   Point mutations in the gene of cytochrome b \[7\]
  Mefloquine                   Duplications in Pfmdr, which encodes the Pgh \[14\]
  Arylaminoalcohols            Duplications in Pfmdr, which encodes the Pgh \[8\]
  Pyrimethamine                Sequential acquisition of mutations in the DHFR gene \[16\]
  Cycloguanil                  Sequential acquisition of mutations in the DHFR gene \[7, 9\]
  Artemisinin                  Not clearly understood; probably by mutation in C580y or point mutations and copy number variations in Pfmdr-1 \[17, 18, 19\]

PfCRT, *Plasmodium falciparum* chloroquine resistance transporter; Pfmdr-1, *Plasmodium falciparum* multidrug resistance gene-1; Pgh, p-glycoprotein pump , DHFR, dihydrofolate reductase.
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